Home / Publication / Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

刊物

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Author(s): Jos Lommerse, Diana Clarke, Thomas Kerbusch, Henri Merdjan, Han Witjes, Hedy Teppler, Mark Mirochnick, Edward P. Acosta, Larissa Wenning, Sharon Nachman, Anne Chain

Year: 2019 年 9 月 8 日

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

案例研究

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

视频

Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development

视频

Meet Floris Fauchet: From Model-Based Drug Development to Martial Arts

视频

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development

Meet Floris Fauchet: From Model-Based Drug Development to Martial Arts

订阅时事通讯

快捷链接

解决方案

联系我们